Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure

International Journal of Molecular Sciences

Volumn 13, Issue 12, 2012, Pages 16624-16635

  Melguizo, Consolación ^a   Prados, Jose ^a   Luque, Raquel ^b   Ortiz, Raúl ^c   Caba, Octavio ^c   Álvarez, Pablo J ^a   Gonzalez, Beatriz ^b   Aranega, Antonia ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

Author keywords

Carboplatin; Lung cancer; MDR; MRP; Paclitaxel; Resistance

Indexed keywords

CARBOPLATIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; PACLITAXEL; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MDR1 GENE; MRP3 GENE; MULTIDRUG RESISTANCE; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEINS; PACLITAXEL;

EID: 84871694972     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131216624     Document Type: Article

References (37)

1. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
2. Monzo, M.; Rosell, R.; Taron, M. Drug resistance in non-small cell lung cancer. Lung Cancer 2001, 34, S91-S94.
3. Ikuta, K.; Takemura, K.; Sasaki, K.; Kihara, M.; Nishimura, M.; Ueda, N.; Naito, S.; Lee, E.; Shimizu, E.; Yamauchi, A. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol. Pharm. Bull. 2005, 28, 707-712.
4. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv. Drug Deliv. Rev. 2012, 55, 3-29.
5. Amiri-Kordestani, L.; Basseville, A.; Kurdziel, K.; Fojo, A.T.; Bates, S.E. Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist. Updat. 2012, 15, 50-61.
6. Horwitz, S.B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H.J.; Yang, C.P. Taxol: Mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr. 1993, 15, 55-61.
7. Kamazawa, S.; Kigawa, J.; Minagawa, Y.; Itamochi, H.; Shimada, M.; Takahashi, M.; Sato, S.; Akeshima, R.; Terakawa, N. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 2000, 59, 329-335.
8. Hilgeroth, A.; Hemmer, M.; Coburger, C. The impact of the induction of multidrug resistance transporters in therapies by used drugs: Recent studies. Mini Rev. Med. Chem. 2012, 12, 1127-1134.
9. Dingemans, A.M.; van Ark-Otte, J.; van der Valk, P.; Apolinario, R.M.; Scheper, R.J.; Postmus, P.E.; Giaccone, G. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann. Oncol. 1996, 7, 625-630.
10. Young, L.C.; Campling, B.G.; Voskoglou-Nomikos, T.; Cole, S.P.C.; Deeley, R.G.; Gerlach, J.H. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response. Clin. Cancer Res. 1999, 5, 673-680.
11. Young, L.C.; Campling, B.G.; Cole, S.P.; Deeley, R.G.; Gerlach, J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 2001, 7, 1798-1804.
12. Wang, M.; Hong, X.; Sun, Q.; Li, R.; Yang, Z.; Chen, G. Establishment of animal model of a human lung adenocarcinoma drug-resistant cell line Anip973/NVB and investigation on mechanism of drug resistance. Zhongguo Fei Ai Za Zhi 2012, 15, 146-151.
13. Chen, Z.J.; Le, H.B.; Zhang, Y.K.; Qian, L.Y.; Sekhar, K.R.; Li, W.D. Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. J. Int. Med. Res. 2011, 39, 1693-1700.
14. Scheper, R.J.; Broxterman, H.J.; Scheffer, G.L.; Kaaijk, P.; Dalton, W.S.; van Heijningen, T.H.; van Kalken, C.K.; Slovak, M.L.; de Vries, E.G.; van der Valk, P.; et al. Overexpression of a M(r) 110,000 vesicular protein in non-Pglycoprotein-mediated multidrug resistance. Cancer Res. 1993, 53, 1475-1479.
15. Thatcher, N.; Heighway, J. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 2010, 15, 1034-1042.
16. Kaye, S.; Aamdal, S.; Jones, R.; Freyer, G.; Pujade-Lauraine, E.; de Vries, E.G.; Barriuso, J.; Sandhu, S.; Tan, D.S.; Hartog, V.; et al. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br. J. Cancer 2012, 106, 1728-1734.
17. Tiseo, M.; Franciosi, V.; Grossi, F.; Ardizzoni, A. Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice. Eur. J. Cancer 2006, 42, 8-16.
18. Li, X.-Q.; Li, J.; Chen, P. Expression and clinical significance of MRP1 and LRP mRNA in nonsmall cell lung cancer. Pract. J. Cancer 2008, 23, 145-147.
19. Ueda, K.; Cardarelli, C.; Gottesman, M.M.; Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 1987, 84, 3004-3008.
20. Ling, V. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer 1992, 69, 2603-2609.
21. Lorico, A.; Rappa, G.; Flavell, R.A.; Sartorelli, A.C. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res. 1996, 56, 5351-5355.
22. Kawanobe, T.; Kogure, S.; Nakamura, S.; Sato, M.; Katayama, K.; Mitsuhashi, J.; Noguchi, K.; Sugimoto, Y. Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochem. Biophys. Res. Commun. 2012, 418, 736-741.
23. Wang, Y.; Chen, Q.; Jin, S.; Deng, W.; Li, S.; Tong, Q.; Chen, Y. Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells. Scand. J. Gastroenterol. 2012, 47, 802-808.
24. Podolski-Renic, A.; Andelkovic, T.; Bankovic, J.; Tanic, N.; Ruždijic, S.; Pešic, M. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomed. Pharmacother. 2011, 65, 345-353.
25. Kars, M.D.; Iseri, O.D.; Gündüz, U. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells. Eur. J. Pharmacol. 2011, 657, 4-9.
26. Rolff, J.; Dorn, C.; Merk, J.; Fichtner, I. Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers. J. Oncol. 2009, 2009, 814140.
27. Volm, M.; Koomägi, R.; Mattern, J.; Efferth, T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br. J. Cancer 2002, 87, 251-257.
28. Meschini, S.; Marra, M.; Calcabrini, A.; Monti, E.; Gariboldi, M.; Dolfini, E.; Arancia, G. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol. In Vitro 2002, 16, 389-398.
29. Chiou, J.F.; Liang, J.A.; Hsu, W.H.; Wang, J.J.; Ho, S.T.; Kao, A. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 2003, 181, 267-273.
30. Shimomura, M.; Yaoi, T.; Itoh, K.; Kato, D.; Terauchi, K.; Shimada, J.; Fushiki, S. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. Int. J. Oncol. 2012, 40, 995-1004.
31. Maráz, A.; Furák, J.; Pálföldi, R.; Eller, J.; Szántó, E.; Kahán, Z.; Thurzó, L.; Molnár, J.; Tiszlavicz, L.; Hideghéty, K. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Res. 2011, 31, 1431-1436.
32. Boyerinas, B.; Park, S.M.; Murmann, A.E.; Gwin, K.; Montag, A.G.; Zillhardt, M.; Hua, Y.J.; Lengyel, E.; Peter, M.E. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int. J. Cancer 2012, 130, 1787-1797.
33. Parker, R.J.; Eastman, A.; Bostick-Bruton, F.; Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 1991, 87, 772-777.
34. Bogush, T.A.; Konukhova, A.V.; Ravcheeva, A.B.; Zabotina, T.N.; Kadagidze, Z.G.; Bogush, E.A.; Komov, D.V.; Polotskii, B.E.; Laktionov, K.K.; Davydov, M.I. Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs. Antibiot. Khimioter. 2003, 48, 11-15.
35. Marsh, R.E.; Tuszynski, J.A.; Sawyer, M.B.; Vos, K.J. Emergence of power laws in the pharmacokinetics of paclitaxel due to competing saturable processes. J. Pharm. Pharm. Sci. 2008, 11, 77-96.
36. Fukuda, M.; Oka, M.; Soda, H.; Terashi, K.; Kawabata, S.; Nakatomi, K.; Takatani, H.; Tsurutani, J.; Tsukamoto, K.; Noguchi, Y.; et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin. Cancer Res. 1999, 5, 3963-3969.
37. Prados, J.; Melguizo, C.; Marchal, J.A.; Vélez, C.; Alvarez, L.; Aránega, A. Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D. Int. J. Cancer 1998, 75, 379-383.